Similarly, this study demonstrates for the first time that TTE and its major constituents reduced PEPCK and G6Pase levels and activated Akt/AMPK, resulting in improved insulin resistance and hepatic gluconeogenesis in both in vitro and in vivo. The gene discussed is G6PC1; the disease is Insulin resistance.